Claim Listing

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently Amended) A therapeutic composition comprising:

a polypeptide capable of binding to at least one of $\alpha 6\beta 1$ integrin receptor and $\alpha 6\beta 4$ integrin receptor, wherein the polypeptide comprises the ~~G domain~~ G3 subdomain of the laminin-5 $\alpha 3$ chain or a fragment, mutant, homolog, ortholog, analog, or allele thereof; and

a pharmaceutically compatible carrier.

2. (Original) The therapeutic composition of claim 1, wherein the polypeptide comprises SEQ ID NO:2 or a fragment, mutant, homolog, ortholog, analog, or allele thereof.

3. (Original) The therapeutic composition of claim 1, wherein the polypeptide comprises at least about 70% sequence identity with SEQ ID NO:2.

4. (Withdrawn) The therapeutic composition of claim 1, wherein the polypeptide comprises SEQ ID NO:4 or a fragment, mutant, homolog, ortholog, analog, or allele thereof.

5. (Withdrawn) The therapeutic composition of claim 1, wherein the polypeptide comprises at least about 70% sequence identity with SEQ ID NO:4.

6. (Withdrawn) The therapeutic composition of claim 1, wherein the polypeptide comprises SEQ ID NO:6 or a fragment, mutant, homolog, ortholog, analog, or allele thereof.

7. (Withdrawn) The therapeutic composition of claim 1, wherein the polypeptide comprises at least about 70% sequence identity with SEQ ID NO:6.

8. (Original) The therapeutic composition of claim 1, wherein the composition is a solid.

9. (Original) The therapeutic composition of claim 8, wherein the pharmaceutically compatible carrier comprises a gelatin.

10. (Original) The therapeutic composition of claim 1, wherein the pharmaceutically compatible carrier comprises water.

11. (Original) The therapeutic composition of claim 1, wherein the pharmaceutically compatible carrier comprises an oil.

12. (Original) The therapeutic composition of claim 1, wherein the pharmaceutically compatible carrier comprises a sustained release matrix.

13. (Original) The therapeutic composition of claim 1, further comprising one or more chemotherapeutic agents for treatment of disease.

14. (Original) The therapeutic composition of claim 1, further comprising one or more radioactive agents for treatment of cancer.

15. (Currently Amended) A therapeutic agent comprising:

a fused or chimeric polypeptide comprising

a first component comprising a polypeptide capable of binding to at least one of $\alpha 6\beta 1$ integrin receptor and $\alpha 6\beta 4$ integrin receptor, wherein the polypeptide comprises the ~~G domain~~ G3 subdomain of the laminin-5 $\alpha 3$ chain or a fragment, mutant, homolog, ortholog, analog, or allele thereof, and

a second component chemically bound to said first component, wherein said second component comprises an agent for use in the destruction or neutralization of a pathogen comprising at least one of $\alpha 6\beta 1$ integrin receptors and $\alpha 6\beta 4$ integrin receptors on the surface of the pathogen.

16. (Original) The therapeutic agent of claim 15, wherein the second component is a polypeptide.

17. (Withdrawn) The therapeutic agent of claim 15, wherein the second component is a non-protein agent.

18. (Original) The therapeutic agent of claim 15, wherein the second component is selected from the group consisting of IL-2, IL-3 IL-15, IL-12, IFN-γ, GM-CSF, CD40, CD40 ligand (CD40L), C3 Complement components, CD80, CD86, FAS, FAS ligand (FASL), superantigens, muramyl dipeptide (MDP), lipopolysaccharide (LPS), or mannose

19. (Original) The therapeutic composition of claim 15, wherein the first component comprises at least about 70% sequence identity with SEQ ID NO:2.

20. (Withdrawn) The therapeutic composition of claim 15, wherein the first component comprises at least about 70% sequence identity with SEQ ID NO:4.

21. (Withdrawn) The therapeutic composition of claim 15, wherein the first component comprises at least about 70% sequence identity with SEQ ID NO:6.

22-42. Canceled